Skip to main content
. 2016 Mar 18;157(5):1789–1798. doi: 10.1210/en.2015-1965

Figure 6.

Figure 6.

Proliferation and apoptosis of pancreatic and pituitary NETs in Men1+/− mice. Proliferative and apoptotic rates were assessed by BrdU labeling and TUNEL assays, respectively. Pancreatic and pituitary NETs were collected from Men1+/− mice age 21 mo given BrdU for 28 d before necropsy. The proliferation and apoptotic rates were compared between PBS and pasireotide-treated mice. A, Proliferation rates in pancreatic and pituitary NETs from PBS-treated Men1+/− mice (open bars) (n = 36 sections from six mice) and pasireotide-treated Men1+/− mice (filled bars) (n = 36 sections from six mice). B, Apoptotic rates in pancreatic and pituitary NETs from PBS-treated Men1+/− mice (open bars) (n = 19 pancreatic NET sections from three mice, and 40 pituitary NET sections from five mice) and pasireotide-treated Men1+/− mice (filled bars) (n = 21 pancreatic NET sections from five mice, and 39 pituitary NET sections from six mice). Pancreatic and pituitary NETs demonstrated a significant 4-fold increase in apoptosis with pasireotide treatment when compared with PBS-treatment. Error bars represent SEM; ***, P < .001.